164513-48-8

Usage

Uses

Used in Organic Synthesis:
(3-Bromo-4-Methylphenoxy)(tert-butyl)dimethylsilane is used as a reagent in organic synthesis for the formation of carbon-silicon bonds. Its unique structure allows it to participate in various organic transformations, providing a stable and reliable platform for chemical reactions.
Used in Chemical Research:
In the field of chemical research, (3-Bromo-4-Methylphenoxy)(tert-butyl)dimethylsilane serves as a valuable precursor for further functionalization reactions. Its presence of a bromine atom makes it a suitable candidate for reactions that require the introduction of new functional groups or the modification of existing ones, thus expanding the scope of synthetic pathways available to researchers.
Used in Industrial Applications:
(3-BroMo-4-Methylphenoxy)(tert-butyl)diMethylsilane also finds utility in industrial applications where its stability and reactivity are advantageous. Its role in the synthesis of various organic compounds makes it a key component in the production of pharmaceuticals, agrochemicals, and other specialty chemicals that require precise and controlled synthetic methods.
Overall, (3-Bromo-4-Methylphenoxy)(tert-butyl)dimethylsilane is a significant player in the realm of organic chemistry, offering a robust and versatile platform for a wide range of applications across different industries.

Upstream product

• 60710-39-6 3-bromo-p-cresol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 1373403-28-1 C₁₉H₃₃BO₃Si 
• 1373403-19-0 C₂₄H₂₀BrNO₄ 

Relevant academic research and scientific papers

ANALGESIC COMPOUNDS, METHODS, AND FORMULATIONS

Provided are analgesic compounds, and salts thereof, of formula: (I) wherein A is: (A) Additionally, pharmaceutical formulations and methods of use employing the above compounds are provided.

INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds defined by formula (I) wherein the variables R1, R2, R3, m, and n are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are activato

INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds defined by formula (I) wherein the variables R1, R2, R3, m, and n are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are activators of the receptor GPR40 and thus are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

Asymmetric synthesis of chiral 9,10-dihydrophenanthrenes using Pd-catalyzed asymmetric intramolecular Friedel-Crafts allylic alkylation of phenols

We developed a novel asymmetric synthetic method for multisubstituted 9,10-dihydrophenanthrenes based on the Pd-catalyzed asymmetric intramolecular Friedel-Crafts allylic alkylation of phenols, which produces 10-vinyl or 10-isopropenyl chiral 9,10-dihydro

ANALGESIC COMPOUNDS, METHODS, AND FORMULATIONS

Provided are compounds, and salts thereof, of formula (I): wherein (A) is R1 is hydrogen, C1-C5 alkyl, C1-C5 alkoxy, C1-C5 haloalkyl, C1-C5 alkanol, -(C1-C5 alkyl)phenyl, or phenyl, or a group of the formula -C(O)-R12, where R12 may be C1-C5 alkyl, C1-C5 alkoxy, C1-C5 haloalkyl, C1-C5 alkanol, -(C1-C5 alkyl)phenyl, or phenyl; R2 and R3 are independently hydrogen, C1-C5 alkyl, C1-C5 alkoxy, halogen, C1-C5 haloalkyl, or C1-C5 haloalkoxy; R4 and R5 are independently hydrogen, C1-C5 alkyl, or -(C1-C5 alkyl)phenyl; R6 is hydrogen, hydroxy, or is absent; R7 is hydrogen; R8 and R9 are independently hydrogen or methyl; R10 is hydrogen; R11 is hydrogen or C1-C5 alkyl; or R7 and R10 combine to form -CH2- or -(CH2)2-; or R8 and R9 combine to form a cyclopropyl group with the carbon to which they are attached; or R10 and R11 combine to form -CH2- or -(CH2)3-. Additionally, pharmaceutical formulations and methods of use employing the above compounds are provided.

ANALGESIC COMPOUNDS, METHODS, AND FORMULATIONS

Provided are analgesic compounds, and salts thereof, of formula: ( I ) wherein A is: ( A ) Additionally, pharmaceutical formulations and methods of use employing the above compounds are provided.

OXADIAZOLIDINEDIONE COMPOUND

[Problem] A compound which can be used as a pharmaceutical, particularly a insulin secretion promoter or a agent for preventing/treating disease in which GPR40 is concerned such as diabetes or the like, is provided. [Means for resolution] It was found that an oxadiazolidinedione compound which is characterized by the possession of a benzyl or the like substituent binding to the cyclic group via a linker at the 2-position of the oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof, has excellent GPR40 agonist action. In addition, since the oxadiazolidinedione compound of the present invention showed excellent insulin secretion promoting action and blood glucose level-lowering action, it is useful as an insulin secretion promoter or an agent for preventing/treating diabetes.